Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Overcoming immune resistance in prostate cancer: Challenges and advances
Miyad Movassaghi
, Rainjade Chung
, Christopher B. Anderson
, Mark Stein
, Yvonne Saenger
, Izak Faiena
Research output
:
Contribution to journal
›
Review article
›
peer-review
22
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Overcoming immune resistance in prostate cancer: Challenges and advances'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Advanced Cancer
33%
Advanced Prostate Cancer
66%
Antibody-drug Conjugate
33%
Cancer-specific
33%
Cellular Immunity
66%
Checkpoint Inhibitors
33%
Chemotherapy
33%
Chemotherapy Resistance
33%
Chimeric Antigen Receptor T-cell Therapy
33%
Clinical Response
33%
Durable Response
33%
Hormonal Therapy
33%
Immune Resistance
100%
Immune Response
33%
Immune System
33%
Immunosuppressive Cells
33%
Immunosuppressive Microenvironment
66%
Immunotherapeutic Strategy
33%
Lethality
33%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
33%
Multiple Strategies
33%
Ongoing Trials
33%
Prostate Cancer
100%
Prostate Tumor
33%
Radiotherapy
33%
Specific Mechanisms
33%
Treatment Efficacy
33%
Treatment Modalities
66%
Tumor mutational Burden
33%
Tumor-specific
33%
Medicine and Dentistry
Advanced Cancer
16%
Cellular Immunity
33%
Chimeric Antigen Receptor T-Cell Immunotherapy
16%
Combination Therapy
16%
Hormone Therapy
16%
Immune Response
16%
Immune System
16%
Immunoglobulin
16%
Immunosuppressive Drug
33%
Immunotherapy
66%
Lethality
16%
Prostate Cancer
100%
Prostate Tumor
16%
Radiation Therapy
16%
Specific Tumor
16%
Treatment Modality
33%
Tumor Microenvironment
33%
Tumor Mutational Burden
16%
Immunology and Microbiology
Adoptive Immunity
50%
Chimeric Antigen Receptor T-Cell Therapy
25%
Immune Response
25%
Immune System
25%
Immunosuppressive Drug
50%
Immunotherapy
100%
Intravenous Immunoglobulin
25%
Prostate
75%
Tumor Mutational Burden
25%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
16%
Chemotherapy
16%
Chimeric Antigen Receptor
16%
Combination Therapy
16%
Hormone Cancer Therapy
16%
Immunoglobulin
16%
Immunosuppressive Agent
33%
Immunotherapy
66%
Lethality
16%
Neoplasm
16%
Prostate Cancer
100%
Prostate Tumor
16%
Tumor Microenvironment
33%